Opioids: an unexplored option for treatment of dyspnea in IPF

References

• Ringbæk T, Sachs C, Lange P, Hansen B. Lungefibrose, Lægehåndbogen. Available from: https://www.sundhed.dk/sundhedsfaglig/laegehaandbogen/lunger/tilstande-og-sygdomme/interstitielle-sygdomme/lungefibrose/ [cited 29 July 2015].
   Google Scholar
• Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, etal. Prognostic significance of histopathologic subsets in IPF. Am J Respir Care Med. 1998; 157: 199–203.
   PubMed Web of Science ®Google Scholar
• Bendstrup E, Madsen HD, Iversen M, Shaker S. Idiopatisk pulmonal fibrose. Guideline from the Danish Society of Respiratory diseases. Available from: http://www.lungemedicin.dk/fagligt/57-idiopatisk-pulmonal-fibrose-ipf.html [cited 16 September 2015].
   Google Scholar
• Bajwah S, Higginson IJ, Ross JR, Wells AU, Birring SS, Patel A, etal. Specialist palliative care is more than drugs: a retrospective study of ILD patients. Lung. 2012; 190: 215–20. [PubMed Abstract].
   Google Scholar
• Lee AS, Mira-Avendano I, Ryu JH, Daniels CE. The burden of idiopathic pulmonary fibrosis: an unmet public health need. Resp Med. 2014; 108: 955–67.
   Web of Science ®Google Scholar
• Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, etal. A simple assessment of dyspnea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 36: 1067–72. [PubMed Abstract].
   Google Scholar
• Manali ED, Stathopoulos GT, Kollintza A, Kalomenidis I, Emili JM, Sotiropoulou C, etal. The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir Med. 2007; 102: 586–92. [PubMed Abstract].
   Google Scholar
• Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, etal. An official American Thoracic Society Statement: update on the mechanisms, assessment and management of dyspnea. Am J Respir Crit Care Med. 2012; 185: 435–52. [PubMed Abstract].
   Google Scholar
• Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 1990; 142: 1009–14. [PubMed Abstract].
   Google Scholar
• von Leopoldt A, Sommer T, Kegat S, Baumann HJ, Klose H, Dahme B, etal. Dyspnea and pain share emotion-related brain network. Neuroimage. 2009; 48: 200–6.
   Web of Science ®Google Scholar
• Adcock JJ. Peripheral opioid receptors and the cough reflex. Respir Med. 1991; 85: 43–6. [PubMed Abstract].
   Google Scholar
• Mahler DA, Murray JA, Waterman LA, Ward J, Kraemer WJ, Zhang X, etal. Endogenous opioids modify dyspnea during treadmill exercise in patients with COPD. Eur Respir J. 2009; 33: 771–7. [PubMed Abstract].
   Google Scholar
• Ryerson CJ, Donesky D, Pantilat SZ, Collard HR. Dyspnea in idiopathic pulmonary fibrosis: a systematic review. J Pain Symptom Manage. 2012; 43: 771–82. [PubMed Abstract].
   Google Scholar
• Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Pall Med. 2005; 19: 128–30.
   PubMed Web of Science ®Google Scholar
• Jennings A, Davies A, Higgins J, Gibbs J, Broadle K. A systematic review of the use of opioids in the management of dyspnea. Thorax. 2002; 57: 939–44. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Ogawa T, etal. Dyspnea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. Respir Med. 2007; 101: 833–8. [PubMed Abstract].
   Google Scholar
• Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, etal. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011; 42: 388–99. [PubMed Abstract].
   Google Scholar
• Young IH, Daviskas E, Keena VA. Effect of low dose nebulized morphine on exercise endurance in patients with chronic lung disease. Thorax. 1989; 44: 387–90. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. J Respir Crit Care Med. 1998; 157: 1877–80.
   PubMed Web of Science ®Google Scholar
• Noseda A, Carpiaux JP, Markstein C, Meyvaert A, de Maertelaer V. Disabling dyspnea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J. 1997; 10: 1079–83. [PubMed Abstract].
   Google Scholar
• Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C, etal. Randomized, double-blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnea. Br Med J. 2003; 327: 523–7.
   PubMed Web of Science ®Google Scholar
• Harris-Eze AQ, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD, etal. Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med. 1995; 152: 1940–5. [PubMed Abstract].
   Google Scholar
• Light RW, Stansbury DW, Webster JS. Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest. 1996; 109: 975–81. [PubMed Abstract].
   Google Scholar
• Jankelson D, Hosseini K, Mather LE, Seale JP, Young IH. Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J. 1997; 10: 2270–4. [PubMed Abstract].
   Google Scholar
• Leung R, Hill P, Burdon J. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996; 51: 596–600. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in pink puffers. Br Med J. 1983; 286: 675–7.
   PubMed Web of Science ®Google Scholar
• Eiser N, Denman WT, West C, Luce P. Oral diamorphine: lack of effect on dyspnea and exercise tolerance in the pink puffer syndrome. Eur Respir J. 1991; 4: 926–31. [PubMed Abstract].
   Google Scholar
• Masood AR, Reed JW, Thomas SH. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995; 50: 629–34. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Jensen D, Alsuhail A, Viola R, Dudgeon DJ, Webb KA, O'Donnel DE. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manag. 2012; 43: 706–19.
   PubMed Web of Science ®Google Scholar
• Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969; 62: 989–93. [PubMed Abstract].
   Google Scholar
• Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnea during exercise. Clin Sci. 1989; 76: 277–82. [PubMed Abstract].
   Google Scholar
• Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manag. 2013; 46: 957–63.
   PubMed Web of Science ®Google Scholar
• Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale and Visual Analogue Scale. COPD. 2005; 2:1: 105–10.
   Google Scholar
• Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, etal. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005; 4: 586–93.
   Google Scholar